### What you need to know
In venous thromboembolism, a blood clot usually forms in the deep veins of the legs or pelvis. This is known as deep vein thrombosis, and the blood clot can dislodge from these sites, resulting in pulmonary embolism.
In 2020, the National Institute for Health and Care Excellence (NICE) first published guidance on the diagnosis and management of venous thromboembolic disease.1 Since then, new evidence has emerged which indicates that people with covid-19 have a higher risk of developing venous thromboembolism and elevated D-dimer levels, and that this risk increased with severity of covid-19 infection. In the 2021 British Thoracic Society guidelines on venous thromboembolism in patients with covid-19, one meta-analysis of 49 studies reported an incidence of venous thromboembolism of 17% in people with covid-19, and that the incidence was higher in patients in intensive care (28%) compared with those on a medical ward (7%).2 D-dimer, a protein fragment that ca
Sarah Boyce, president and CEO at Avidity Biosciences, discusses her leading role at the company, as well as antibody oligonucleotide conjugate drug, AOC 1044, currently in development for Duchenne muscular dystrophy (DMD) with mutations amenable to exon 44 skipping (DMD44).
New AOC 1001 data demonstrate improvement in additional functional measures including hand grip, muscle strength and patient reported outcomes, augmenting previously reported positive data showing.
Avidity Biosciences Announces New Positive AOC 1001 Data Demonstrating Improvement in Multiple Additional Functional Endpoints and Favorable Long-term Safety and Tolerability in People with Myotonic D streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.